# Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease

> **NCT04815187** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **House Ear Institute** · enrollment: 39 (actual)

## Conditions studied

- Meniere Disease
- Allergic Rhinitis
- Vertigo

## Interventions

- **DRUG:** Montelukast
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04815187
- **Lead sponsor:** House Ear Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-07
- **Primary completion:** 2025-09-03
- **Final completion:** 2025-12-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04815187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04815187, "Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04815187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*